Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

Rituximab 56Cyclophosphamide 39fludarabine 23fludarabine phosphate 18Peripheral Blood Stem Cell Transplantation 17Lenalidomide 14Melphalan 13Etoposide 12venetoclax 11Whole-Body Irradiation 11Mycophenolic Acid 11obinutuzumab 10Vincristine 10Prednisone 10Bendamustine Hydrochloride 10Doxorubicin 9Cytarabine 9Cyclosporine 9Bortezomib 9Filgrastim 8pembrolizumab 7Nivolumab 7Gemcitabine 7Busulfan 7acalabrutinib 6Tacrolimus 6Interleukin-2 6Dexamethasone 6Carmustine 6Alemtuzumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Non-Hodgkin × TAK-981 × Clear all
NCT04074330 2024-06-14

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Takeda

Phase 1/2 Terminated
38 enrolled 44 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡